OBJECTIVE： To observe therapeutic efficacy of kallidinogenase combined with difrarel in the treatment of diabetic retinopathy. METHODS： 120 patients with diabetic retinopathy were randomly divided into  control group A， control group B and combination group， with 40 cases in each group. Control group A was given Kallidinogenase enteric-coated tablet 240 IU，tid， control group B was given Difrarel tablet 1.2 g， bid， and combination group equivalent dose of Kallidinogenase enteric-coated tablet combined with Difrarel tablet. The vision， peak systolic velocity （PSV）， end diastolic velocity （EDV） and resistance index （RI） of ophthalmic artery （OA）， central retinal artery （CRA） and posterior ciliary artery （PCA） were compared among 3 groups before and after treatment. Therapeutic efficacy was observed in 3 groups. RESULTS： After treatment， vision of 3 groups significantly improved； PSV and EDV of OA， CRA and PCA increased while RI of OA， CRA and PCR decreased， with statistical significance （P＜0.05）. vision， PSV and EDV of OA， CRA and PCA in combination group were significantly higher than in control group A and control group B after treatment， while RI of  OA， CRA and PCA was significantly lower than control group A and control group B， with statistical significance （P＜0.05）； total effective rate of combination group was significantly higher than that of control group A and control group B， with statistical significance （P＜0.05）. CONCLUSIONS： Kallidinogenase combined with difrarel can improve retinal hemodynamics indicator and clinical efficacy of patients with diabetic retinopathy